[Effect of Performing a Single PSA Screening : The CAP Trial]
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Carlsson S, M de Carvalho T, Roobol M, Hugosson J, Auvinen A, Kwiatkowski M
. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer. 2016; 122(21):3386-3393.
PMC: 5073010.
DOI: 10.1002/cncr.30192.
View
2.
Vickers A, Ulmert D, Sjoberg D, Bennette C, Bjork T, Gerdtsson A
. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013; 346:f2023.
PMC: 3933251.
DOI: 10.1136/bmj.f2023.
View
3.
Lilja H, Ulmert D, Bjork T, Becker C, Serio A, Nilsson J
. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007; 25(4):431-6.
DOI: 10.1200/JCO.2006.06.9351.
View
4.
Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T
. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104(2):125-32.
PMC: 3260132.
DOI: 10.1093/jnci/djr500.
View
5.
Arsov C, Becker N, Hadaschik B, Hohenfellner M, Herkommer K, Gschwend J
. Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial. Eur Urol. 2013; 64(6):873-5.
DOI: 10.1016/j.eururo.2013.05.022.
View